The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals
©2022 The Authors; Published by the American Association for Cancer Research..
Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized the polarity and specificity of memory T cells directed against SARS-CoV-2 viral lysates and peptides to determine correlates with spontaneous, virus-elicited, or vaccine-induced protection against COVID-19 in disease-free and cancer-bearing individuals. A disbalance between type 1 and 2 cytokine release was associated with high susceptibility to COVID-19. Individuals susceptible to infection exhibited a specific deficit in the T helper 1/T cytotoxic 1 (Th1/Tc1) peptide repertoire affecting the receptor binding domain of the spike protein (S1-RBD), a hotspot of viral mutations. Current vaccines triggered Th1/Tc1 responses in only a fraction of all subject categories, more effectively against the original sequence of S1-RBD than that from viral variants. We speculate that the next generation of vaccines should elicit Th1/Tc1 T-cell responses against the S1-RBD domain of emerging viral variants.
SIGNIFICANCE: This study prospectively analyzed virus-specific T-cell correlates of protection against COVID-19 in healthy and cancer-bearing individuals. A disbalance between Th1/Th2 recall responses conferred susceptibility to COVID-19 in both populations, coinciding with selective defects in Th1 recognition of the receptor binding domain of spike. See related commentary by McGary and Vardhana, p. 892. This article is highlighted in the In This Issue feature, p. 873.
| Errataetall: |
CommentIn: Cancer Discov. 2022 Apr 1;12(4):892-894. - PMID 35373282 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer discovery - 12(2022), 4 vom: 01. Apr., Seite 958-983 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 05.04.2022 Date Revised 06.01.2023 published: Print CommentIn: Cancer Discov. 2022 Apr 1;12(4):892-894. - PMID 35373282 Citation Status MEDLINE |
|---|
| doi: |
10.1158/2159-8290.CD-21-1441 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337110786 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337110786 | ||
| 003 | DE-627 | ||
| 005 | 20231226204242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2159-8290.CD-21-1441 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM337110786 | ||
| 035 | |a (NLM)35179201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fahrner, Jean-Eudes |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2022 | ||
| 500 | |a Date Revised 06.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Cancer Discov. 2022 Apr 1;12(4):892-894. - PMID 35373282 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2022 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized the polarity and specificity of memory T cells directed against SARS-CoV-2 viral lysates and peptides to determine correlates with spontaneous, virus-elicited, or vaccine-induced protection against COVID-19 in disease-free and cancer-bearing individuals. A disbalance between type 1 and 2 cytokine release was associated with high susceptibility to COVID-19. Individuals susceptible to infection exhibited a specific deficit in the T helper 1/T cytotoxic 1 (Th1/Tc1) peptide repertoire affecting the receptor binding domain of the spike protein (S1-RBD), a hotspot of viral mutations. Current vaccines triggered Th1/Tc1 responses in only a fraction of all subject categories, more effectively against the original sequence of S1-RBD than that from viral variants. We speculate that the next generation of vaccines should elicit Th1/Tc1 T-cell responses against the S1-RBD domain of emerging viral variants | ||
| 520 | |a SIGNIFICANCE: This study prospectively analyzed virus-specific T-cell correlates of protection against COVID-19 in healthy and cancer-bearing individuals. A disbalance between Th1/Th2 recall responses conferred susceptibility to COVID-19 in both populations, coinciding with selective defects in Th1 recognition of the receptor binding domain of spike. See related commentary by McGary and Vardhana, p. 892. This article is highlighted in the In This Issue feature, p. 873 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antiviral Restriction Factors |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Lahmar, Imran |e verfasserin |4 aut | |
| 700 | 1 | |a Goubet, Anne-Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Yacine |e verfasserin |4 aut | |
| 700 | 1 | |a Carrier, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzenga, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Drubay, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Alves Costa Silva, Carolina |e verfasserin |4 aut | |
| 700 | 0 | |a Lyon COVID Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a de Sousa, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Thelemaque, Cassandra |e verfasserin |4 aut | |
| 700 | 1 | |a Melenotte, Cléa |e verfasserin |4 aut | |
| 700 | 1 | |a Dubuisson, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Geraud, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrere, Gladys |e verfasserin |4 aut | |
| 700 | 1 | |a Birebent, Roxanne |e verfasserin |4 aut | |
| 700 | 1 | |a Bigenwald, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Picard, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Cerbone, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Lérias, Joana R |e verfasserin |4 aut | |
| 700 | 1 | |a Laparra, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard-Tessier, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Kloeckner, Benoît |e verfasserin |4 aut | |
| 700 | 1 | |a Gazzano, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Danlos, François-Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Terrisse, Safae |e verfasserin |4 aut | |
| 700 | 1 | |a Pizzato, Eugenie |e verfasserin |4 aut | |
| 700 | 1 | |a Flament, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Ly, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Tartour, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Benhamouda, Nadine |e verfasserin |4 aut | |
| 700 | 1 | |a Meziani, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed-Belkacem, Abdelhakim |e verfasserin |4 aut | |
| 700 | 1 | |a Miyara, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Gorochov, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Barlesi, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Trubert, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Ungar, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Estrada, Yeriel |e verfasserin |4 aut | |
| 700 | 1 | |a Pradon, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Gallois, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Pommeret, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Colomba, Emeline |e verfasserin |4 aut | |
| 700 | 1 | |a Lavaud, Pernelle |e verfasserin |4 aut | |
| 700 | 1 | |a Deloger, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Droin, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Deutsch, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Gachot, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Spano, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Merad, Mansouria |e verfasserin |4 aut | |
| 700 | 1 | |a Scotté, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Marabelle, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Griscelli, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Blay, Jean-Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, Jean-Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Merad, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a André, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Villemonteix, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Chevalier, Mathieu F |e verfasserin |4 aut | |
| 700 | 1 | |a Caillat-Zucman, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Fenollar, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Guttman-Yassky, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Launay, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Kroemer, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a La Scola, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Derosa, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Zitvogel, Laurence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer discovery |d 2011 |g 12(2022), 4 vom: 01. Apr., Seite 958-983 |w (DE-627)NLM215937023 |x 2159-8290 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:958-983 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2159-8290.CD-21-1441 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 4 |b 01 |c 04 |h 958-983 | ||